Evidence map›Paper›PMID 41059311›Full record

ArticleClinical & translational immunology2025

Single-cell RNA sequencing reveals cell immune status and dysregulated monocytes in patients with myasthenia gravis.

Yufan Guo, Yu Gu, Yuting Jin, Xintao Wu, Yuting Lou, Pu Miao, Ye Wang, Bijun Zhang, Xueting Lin, Chudi Zhang and 1 more

Abstract read
In one paragraph

Article in Clinical & translational immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CFDFrontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yufan GuoDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
Yu GuZhejiang University School of Medicine Hangzhou China.
Yuting JinDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
Xintao WuZhejiang University School of Medicine Hangzhou China.
Yuting LouDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
Pu MiaoDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
Ye WangDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
Bijun ZhangDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
Xueting LinDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
Chudi ZhangDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
Jianhua FengDepartment of Pediatrics The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: As an autoimmune disorder, myasthenia gravis (MG) manifests as an autoimmune attack on postsynaptic neuromuscular junction proteins by pathogenic autoantibodies. This immune attack disrupts neurotransmission, resulting in fatigable skeletal muscle weakness with diurnal fluctuation. However, functional cure biomarkers for patients remain limited. Methods: Peripheral blood collection was performed at three time points in patients with MG: before treatment (Pre), 1 month after treatment (Post) and functional cure (long-term follow-up, LF). Single-cell RNA sequencing was performed. The clinical examination results were collected and summarised. Results: In general, patients with MG exhibited dynamic changes in immune cell composition and inflammatory features. In particular, monocytes were enriched in the LF group, and further subgroup analysis revealed enrichment of CD14 Conclusion: Our study provides a comprehensive cell landscape for patients with MG, identifies two dysregulated monocytes, elucidates the inflammation status and offers a new perspective on understanding the aetiology of functional cure and potential therapeutic strategies for patients with MG.

Indexed as

CD14+FOS+ monocyteCD14+S100A12+ monocyteinflammationmyasthenia gravisscRNA‐seq

Identifiers

PMID41059311
PMCPMC12497684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.